Highly Specific and Effective Targeting of EGFRvIII-Positive Tumors with TandAb Antibodies

To harness the cytotoxic capacity of immune cells for the treatment of solid tumors, we developed tetravalent, bispecific tandem diabody (TandAb) antibodies that recognize EGFRvIII, the deletion variant III of the epidermal growth factor receptor (EGFR), and CD3 on T-cells, thereby directing immune...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Front Oncol
Main Authors: Ellwanger, Kristina, Reusch, Uwe, Fucek, Ivica, Knackmuss, Stefan, Weichel, Michael, Gantke, Thorsten, Molkenthin, Vera, Zhukovsky, Eugene A., Tesar, Michael, Treder, Martin
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2017
Assuntos:
Oncology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5442391/
https://ncbi.nlm.nih.gov/pubmed/28596941
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2017.00100
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados